Linked Life Data

12853695

Source:http://linkedlifedata.com/resource/pubmed/id/12853695

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2003-7-10
pubmed:abstractText
Since the first description of paraneoplastic pemphigus, several cases have been described in the literature. However, curative therapy is usually a challenge to the physicians treating this disease. Several publications are available discussing the efficacy of steroids, cyclophosphamide and cyclosporin A. Recently, a report of the successful use of rituximab was also published. However, the use of cyclosporin A is controversial in the case of B cell malignancies, as there are reports showing the cytotoxic effect of this drug on B cells. However, other authors report no effect, or even unwanted effects resulting in B cell proliferation. We report the case of a 50-year-old Caucasian male. He developed a B cell lymphoma consisting of CD5/CD20-double-positive cells, and 2 months later, it was followed by a very severe paraneoplastic pemphigus affecting the mucosa and the skin. The lymphoma was well managed with CHOP and CVP polychemotherapy, followed by oral chlorambucil; however, the bullous eruptions did not disappear. Oral steroids, cyclophosphamide, plasmapheresis and IVIG therapy were only partially successful, so we decided to use oral cyclosporin A. Starting with 7 mg/kg and maintaining a steady plasma level of no less then 110 ng/l, the bullae completely disappeared within 6 weeks, and the patient has been in remission for 17 months now, taking the oral cyclosporin A continuously. The underlying B cell disorder did not relapse during the therapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0001-5792
pubmed:author
pubmed:copyrightInfo
Copyright 2003 S. Karger AG, Basel
pubmed:issnType
Print
pubmed:volume
109
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
202-5
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:12853695-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:12853695-Chlorambucil, pubmed-meshheading:12853695-Combined Modality Therapy, pubmed-meshheading:12853695-Cyclophosphamide, pubmed-meshheading:12853695-Cyclosporine, pubmed-meshheading:12853695-Doxorubicin, pubmed-meshheading:12853695-Drug Therapy, Combination, pubmed-meshheading:12853695-Humans, pubmed-meshheading:12853695-Immunosuppressive Agents, pubmed-meshheading:12853695-Leukemia, Lymphocytic, Chronic, B-Cell, pubmed-meshheading:12853695-Male, pubmed-meshheading:12853695-Methylprednisolone, pubmed-meshheading:12853695-Middle Aged, pubmed-meshheading:12853695-Paraneoplastic Syndromes, pubmed-meshheading:12853695-Pemphigus, pubmed-meshheading:12853695-Plasma Exchange, pubmed-meshheading:12853695-Prednisone, pubmed-meshheading:12853695-Remission Induction, pubmed-meshheading:12853695-Vincristine
pubmed:year
2003
pubmed:articleTitle
Successful treatment of B cell chronic lymphocytic leukemia-associated severe paraneoplastic pemphigus with cyclosporin A.
pubmed:affiliation
3rd Department of Medicine, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary. gergely@iiibel.dote.hu
pubmed:publicationType
Journal Article, Case Reports